This study was a single-arm trial of autologous NK cell adjuvant therapy for relapsed/refractory non-Hodgkin's B-cell lymphoma. The locations isXiangyang No.1 People's Hospital, Hubei University of Medicine. The population was relapsed/refractory non-Hodgkin's B-cell lymphoma. The sample size was 33. The intervention was R-GemOx regimen combined with autologous NK cells. The dose of autologous NK cells was body surface area x (2-4) x 109 cells. The course of treatment was once every 14 days. The primary outcome measure was ORR. The duration of assessment was for each treatment cycle, 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 3 years, and 5 years of treatment.

Start Date01 Jul 2023

Sponsor / Collaborator

Xiang Yang No.1 People's Hospital

[+1]

ChiCTR2300070715

/ SuspendedNot ApplicableIIT

Effectiveness evaluation of Matrix Metalloproteinase 9 detection kit (colloidal gold method) in the diagnosis of dry eye disease

Start Date01 May 2023

Sponsor / Collaborator

Xiang Yang No.1 People's Hospital

NCT05159947

/ RecruitingPhase 3IIT

Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Trial of the Efficacy and Safety of SPT-07A Injection in Patients With Acute Ischemic Stroke

This is a multicenter, randomized, double-blind, placebo-controlled, parallel controlled clinical trial in Chinese patients with acute ischemic stroke. Objective to evaluate the efficacy and safety of SPT-07A injection compared with placebo in the treatment of patients with acute ischemic stroke.

Start Date20 Jan 2022

Sponsor / Collaborator

Wuhan Xiehe Hospital Tower

[+28]

100 Clinical Results associated with Xiang Yang No.1 People's Hospital

0 Patents (Medical) associated with Xiang Yang No.1 People's Hospital

Literatures (Medical) associated with Xiang Yang No.1 People's Hospital

Hubei Yiyao Xueyuan Xuebao

Research on the current situation and influencing factors of spiritual needs of cancer patients in Shiyan area

Author: Li, Ling ; Zhu, Lihua ; Li, Qun ; Zhang, Xiuxia ; Dong, Yi

Association of systemic inflammatory biomarkers with hearing loss: Results from NHANES 1999–2020 analyses

Author: Li, Xiaodan ; Cheng, Sheng ; Tan, Huazhang ; Wang, Yaojie ; Tian, Jing ; Qin, Chenge ; He, Lisha ; Wang, Qiuyang ; Huang, Guoxin

Abstract

Background:Hearing loss (HL) is a prevalent global health issue with a complex etiology in whichinflammation plays a significant role. The systemic immune inflammatory index (SII), a novel biomarker reflecting systemic inflammation, is hypothesized to correlate with HL. Methods: Utilizing National Health and Nutritional Health Survey (NHANES) data from 1999–2020, this study analyzed the relationship between the SII and HL, categorized ashigh-frequency hearing loss (HFHL) orspeech-frequency hearing loss (SFHL). Blood samples were collected to calculate the SII. Weighted multivariate linear and logistic regression analyses were used to examine the linear relationship between the SII and hearing loss. After the SII was categorized into quartiles, a trend test was applied to assess the linear association between the SII and HL. Subgroup analysis was conducted to explore the correlation between the SII and HL across different sexes. Results: Univariate logistic regression analysis revealed no significant correlation between the SII and the occurrence of hearing loss or SFHL (p>0.05), but there was a correlation between the SII and HFHL. Multivariate logistic regression revealed a significant positive correlation between the third quartile of the SII and hearing loss. In the second quartile, there was a significant positive correlation between the SII and SFHL. For HFHL, a significant positive correlation between the SII and HFHL was present only in the crude model and in the second and third quartiles. Stratified analysis of clinical variables revealed a positive correlation between SII and the onset of hearing loss in those with never alcohol intake and moderate alcohol intake, a positive correlation between the SII and HFHL in those with moderate alcohol intake,and a negative correlation between the SII and SFHL in those with a normal BMI, aged older than 60 years, and who were former smokers. In the RCSplot, a reverse U-shaped association was observed between the SII and the prevalence of hearing loss and SFHL (nonlinear p<0.05). There was a positive correlation between the SII and the incidence of HFHL. After stratification by sex, the SII showed a reverse U-shaped association with hearing loss in males and a positive correlation in females. Conclusion: The SII is positively correlated with HFHL and shows a potential U-shaped relationship with HL and SFHL. In males, there was a reverse U-shaped association between the SII and hearing loss, while in females, there was a positive correlation.

Shijie Zhongyiyao

Effects of Gualou Xiebai Guizhi Decoction on lipid metabolism and plasma heme oxygenase-1 and matrix metalloproteinase-9 levels in elderly patients with coronary heart disease

Author: Su, Renyi ; Xu, Xiping ; Zhu, Bo ; Qiao, Ke ; Yang, Yan

Objective: To explore the clin. effects of modified Gualou Xiebai Guizhi Decoction on lipid metabolism plasma heme oxygenase-1 (HO-1) and matrix metalloproteinase-9 (MMP-9) in elderly patients with coronary heart disease, so as to explore the therapeutic mechanism of Gualou Xiebai Guizhi Decoction on elderly patients with coronary heart disease and lay a foundation for optimizing the therapeutic regimen.Methods: A total of 104 elderly patients with coronary heart disease from Dec. 2015 to Dec. 2017 in Xiangyang First People′s Hospital were selected as the study subjects.According to the order of grouping, odd numbers were included in the control group, and even numbers were included in the observation group, with 52 cases in each group.Both groups of patients were given comprehensive treatment according to the routine diagnosis and treatment guidelines of coronary heart disease.On this basis, modified Gualou Xiebai Guizhi Decoction was added.The 2 groups were treated for 2 mo.The changes of blood lipid metabolism (TC, TG, HDL-C, LDL-C, OGTT), plasma HO-1, MMP-9, and hemodynamics (SV, CO, CI, LVEDP, AC) before and after treatment were compared between the 2 groups.The rates of adverse cardiovascular events and adverse drug reactions/side effects and the clin. curative effect rate after treatment were compared between the 2 groups.Results: 1) After treatment, TC, TG, LDL-C and OGTT of the 2 groups were significantly decreased than those before treatment, and the observation group was lower than the control group (P<0.05).HDL-C was significantly increased than before treatment, and the observation group was higher than the control group (P<0.05).2) After treatment, the level of HO-1 was significantly increased in the observation group than in the control group (P<0.05), and the level of MMP-9 was significantly decreased in the observation group than in the control group (P<0.05).3) After treatment, SV, CO, CI, AC in both groups were significantly higher than before treatment, and the observation group was higher than the control group (P>0.05).LVEDP were significantly decreased than before treatment, and the observation group was lower than the control group (P<0.05).4) The incidence of adverse cardiovascular events in the observation group was significantly lower than that in the control group (P<0.05).5) No serious adverse drug reactions/toxic side effects were collected during the treatment of the 2 groups.There was no significant difference between the 2 groups (P>0.05).6) After treatment, the total effective rate of the observation group was significantly higher than that of the control group (P<0.05).Conclusion: Modified Gualou Xiebai Guizhi Decoction can effectively improve lipid metabolism, enhance hemodynamic function enhance HO-1, reduce MMP-9, reduce the incidence of adverse cardiovascular events in elderly patients with coronary heart disease, and achieve the effect of improving clin. efficacy in many ways.It has high clin. value.

100 Deals associated with Xiang Yang No.1 People's Hospital

100 Translational Medicine associated with Xiang Yang No.1 People's Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 02 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Autologous NK cell(Xiang Yang No.1 People's Hospital)	B-cell lymphoma recurrent More	Phase 2 Clinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis